Renal function with use of a tenofovir-containing initial antiretroviral regimen

AIDS

Volumn 23, Issue 15, 2009, Pages 1971-1975

  Gallant, Joel E ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral; Kidney; Nephrotoxicity; Nucleoside analog reverse transcriptase inhibitor; Protease inhibitor; Renal; Tenofovir

Indexed keywords

ABACAVIR; CREATININE; DIDANOSINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DRUG EXCRETION; DRUG UTILIZATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREND STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70349780794     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832c96e9     Document Type: Article

References (28)

1. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-nayve patients: a randomized trial. JAMA 2004; 292:191-201.
2. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.NEngl J Med 2006; 354:251-260.
3. Ortiz R,DeJesus E, Khanlou H, Veronin E, van Lunzen J, Andrade- Villanueva J, et al. Efficacy and safety of once-daily darunavir/ ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1- infected patients at 48 weeks. AIDS 2008; 22:1389-1397.
4. Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 Weeks. AIDS Res Hum Retroviruses 2007; 23:1505-1514.
5. Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, et al.Once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50: 474-481.
6. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743-746.
7. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
8. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment: case report and review of literature. J Infect 2005; 51:E61-E65.
9. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mouquenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-1333.
10. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, et al. Renal safety of tenofovir in HIV treatment experienced patients. AIDS 2004; 18:1074-1076.
11. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy. HIV Med 2006; 7:105-111.
12. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-95.
13. Gallant JE, Parish MA, Keruly JD, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
14. Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [letter]. Clin Infect Dis 2005; 41:571.
15. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43:278-283.
16. Gilead Sciences. Viread Medication Insert. http://www.gilead. com/pdf/viread-pi.pdf. [Accessed 6 December 2008].
17. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-108.
18. Buchacz K, Young B, Baker RK, Moorman AC, Wood KC, Chmiel J, et al. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) Cohort. J Acquir Immune Defic Syndr 2006; 43:626-628.
19. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr 1998; 17 (Suppl 1):S38-S41.
20. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254.
21. Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005; 49: 3361-3366.
22. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265-272.
23. Tong L, Phan T, Robinson K, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504.
24. Ray AS, Wright MR, Rhodes GR. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. Clin Pharmacol Ther 2008; 84:660.
25. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19:455-462.
26. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817.
27. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-3304.
28. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistanceassociated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71:619-627.